Meeting
2022 ASCO Genitourinary Cancers Symposium
Does concurrent COX inhibition and immune checkpoint blockade improve clinical outcomes in patients with metastatic renal cell carcinoma (mRCC)?
Authors
Premsai Kumar
Morsani College of Medicine, Univeristy of South Florida, Tampa, FL
Premsai Kumar , Yumeng Zhang , Jiannong Li , Brandon J. Manley , Jad Chahoud , Philippe E. Spiess
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 354)
DOI
10.1200/JCO.2022.40.6_suppl.354
Abstract #
354
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Association of neutrophil to eosinophil ratio (NER) with clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with first-line (1L) immune checkpoint inhibitors (ICI) –based regimens.
First Author: Marc Eid
Poster
2021 ASCO Annual Meeting
The impact of antibiotic (Ab) exposure on clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or VEGF targeted therapy (VEGF-TT).
First Author: Matthew Scott Ernst
Poster
2024 ASCO Genitourinary Cancers Symposium
Evolving metastatic renal cell carcinoma (mRCC) treatment landscape in the post vascular endothelial growth factor (VEGF) and immune checkpoint inhibitor (IO) setting.
First Author: Neil J. Shah
Poster
2023 ASCO Annual Meeting
Pan-cancer analysis of IDO1 transcriptome expression and its impact on outcome in patients treated with immune checkpoint inhibitors.
First Author: Yu Fujiwara